Clinical trials: All
Hematologic Malignancy, ALL, Childhood
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma.
- Conditions
- Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma
- Trial name
- NCT06326463
- Testing
- Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia (ALL)
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
The main goal of this study is to improve the outcome of children and adolescents with standard risk (SR) first relapsed acute lymphoblastic leukemia.
- Trial name
- NCT01802814
- Testing
- SR-A + Epratuzumab, SR-B + Epratuzumab
- Where
- 17 sites in Australia, Austria and 15 more
- Volunteers
- 700 people
- Sponsor
- Charite University, Berlin, Germany
Leukemia
Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. This may be effective treatment for leukemia.
- Trial name
- NCT00643240
- Testing
- yttrium Y 90 anti-CD19 monoclonal antibody BU12, 111In-BU-12
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-cell Acute Lymphoblastic Leukemia
Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia
The study is in two parts: a dose escalation then a safety dose expansion. The purpose of the dose escalation part is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single…
- Trial name
- CALM (NCT02746952)
- Testing
- UCART19
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 25 people
- Sponsor
- Institut de Recherches Internationales Servier
Coronary Artery Disease, Acute Coronary Syndrome
Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
New-generation metallic drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention (PCI).
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Chronic Coronary Syndrome, Myocardial Infarction
- Trial name
- PARTHENOPE (NCT04135989)
- Testing
- Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease., Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease., Personalized DAPT duration
- Where
- 13 sites in Italy
- Volunteers
- 2,106 people
- Sponsor
- Federico II University
Leukemia, Renal Toxicity
Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia
RATIONALE: Gathering information about how often kidney dysfunction occurs in children and young adults receiving methotrexate for acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best…
- Trial name
- NCT00993135
- Testing
- methotrexate, medical chart review, assessment of therapy complications
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University Medical Center
Dental Implants, Dental Materials
Hybrid Polyetheretherketone (PEEK)-Acrylic Resin Prostheses and the All-on-4 Concept for Full Arch Rehabilitation
It is necessary to evaluate the outcome of implant supported fixed prosthetic rehabilitations using peek material. To test this, the study design to be used will be a prospective single cohort to evaluate the long term outcome of…
- Conditions
- Dental Implants, Dental Materials, Mandible, Prosthesis Survival
- Trial name
- AO4PEEKDev (NCT04446078)
- Testing
- PEEK- acrylic resin prosthesis supported by 4 dental implants
- Where
- Portugal
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Malo Clinic
Refractory TdT-Positive Leukemia
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
This is a two-part, open-label, Phase I/II study in subjects with relapsed or refractory TdT-positive leukemia for which no standard therapies are expected to result in durable remission.
- Trial name
- NCT00709215
- Testing
- Cordycepin plus Pentostatin
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- OncoVista, Inc.
Leukemia, T Cell
Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of CD7 Positive acute leukemia or mixed lineage leukemia except those who are diagnosed with T-ALL/T-LBL
- Trial name
- NCT04938115
- Testing
- CD7 CART
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL)…
- Trial name
- NCT03384654
- Testing
- Daratumumab, Vincristine, Prednisone
- Where
- 53 sites in United States, Belgium and 8 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
Acute Lymphoblastic Leukemia
Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors
Treatment of acute lymphoblastic leukemia achieves high cure rate, but is potentially neurotoxic. Long-term neurologic morbidity in survivors and its effect on function are inadequately studied.
- Trial name
- NCT00664131
- Testing
- Neurological Examination/Questionnaires
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- St. Jude Children's Research Hospital
Acute B-cell Lymphoblastic Leukemia
Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
B-ALL patients received regular follow-up after allogeneic hematopoietic stem cell transplantation, and in case of recurrence, they were given Blinatumomab.
- Trial name
- NCT06339775
- Testing
- Blinatumomab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suping ZHANG
Leukemia, Lymphoma
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00176475
- Testing
- rituximab, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL)
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Subjects are having a bone marrow or SCT for either a type of cancer of the blood called Leukemia or a cancer of the lymph nodes called non- Hodgkin's Lymphoma.
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
- Trial name
- MULTIPRAT (NCT00840853)
- Testing
- CD19CAR/virus specific T cells, Benadryl and Tylenol
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- Baylor College of Medicine
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
This phase Ib trial investigates the side effects and best dose of pegcrisantaspase when given together with fludarabine and cytarabine for the treatment of patients with leukemia that has come back (relapsed) or has not…
- Conditions
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT04526795
- Testing
- Cytarabine, Fludarabine, Pegcrisantaspase
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia (ALL), Critical Illness
Animal Assisted Interactions With Animal Robot in the Intensive Care Unit (ICU)
The purpose of this study is to: 1. Establish the feasibility and acceptability of a therapeutic robot, Paro, for critically ill patients admitted to the Pediatric Intensive Care Unit 2.
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Critical Illness, Physical Therapy Modalities, Occupational Therapy
- Trial name
- PARO (NCT05075395)
- Testing
- PARO therapy seal
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Nebraska
All Conditions Treated at the Heart Centres
DenHeart - Self-reported Health and Quality of Life at Hospital Discharge From a Heart Centre in Denmark
The objective of this study is to describe: 1) Differences in perceived health at hospital discharge between diagnostic groups and in-hospital predicting factors.
- Trial name
- DenHeart (NCT01926145)
- Where
- 5 sites in Denmark
- Volunteers
- 16,712 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Young People With All Long-term Health Conditions
The National Transition Evaluation Study
This is a multi-centre study within England to evaluate whether the Burdett Trust National Transition Network and the implementation of the Model of Improvement for Transition has an impact on the experience of transitioning from…
- Trial name
- NTES (NCT05867745)
- Testing
- Interview, Survey, Letter to a friend (autoethnography)
- Where
- 7 sites in United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Allogeneic or Autologous HSCT
Gram-negative Bacteremia in HSCT Recipients
A significant increase in resistant bacteria emerging in HSCT recipients. For example, 25% - 42% of all enterobacteriaceae produce extended spectrum beta-lactamases; 8 - 72% of Pseudomonas aeruginosa are resistant to at least one…
- Trial name
- GNB (NCT02257931)
- Where
- 10 sites in Belgium, China and 7 more
- Volunteers
- 591 people
- Sponsor
- European Society for Blood and Marrow Transplantation
ALL, Adult
Video-recOrded hospItal dischaRge (VOIR)
This study evaluates the suitability and acceptability of video-recorded discharge via the Patient Knows Best app. Through a randomized control trial, patients receive either standard discharge care or standard care supplemented…
- Trial name
- VOIR (NCT06512272)
- Testing
- Video recorded shared using a mobile application
- Volunteers
- 60 people
- Sponsor
- Anglia Ruskin University